News
-
GHK-Cu Side Effects: Topical vs Injectable
GHK-Cu side effects are usually mild with topical cosmetics, but injectable GHK-Cu has no long-term human safety data. Route is the difference that matters.
-
Tesamorelin Side Effects: Rates, Risks, Monitoring
The most common tesamorelin side effects are injection-site reactions and joint pain; glucose, IGF-1 and cancer history are the monitoring issues that can change the plan.
-
Tirzepatide for Type 2 Diabetes: Trial Results
Across the SURPASS trials, adults assigned to tirzepatide had average HbA1c reductions of roughly 1.9 to 2.4 percentage points over 40 to 52 weeks. The right comparison depends on a person's existing diabetes treatment and clinical risks.
-
Can You Use HSA for GLP-1? Eligibility Rules
A prescribed GLP-1 may be HSA- or FSA-eligible when it treats a physician-diagnosed condition. The diagnosis, documentation and administrator's rules determine whether a claim is accepted.
-
GLP-1 Drops: What the Absorption Evidence Shows
GLP-1 drops promise a needle-free shortcut, but the delivery system is the whole question. No published human clinical evidence yet shows that sublingual semaglutide drops achieve meaningful absorption or weight-loss efficacy.
-
How Long Does GLP-1 Nausea Last?
A semaglutide nausea episode lasted a median of 8 days in pooled weight-management trials. Symptoms usually cluster around starting treatment and dose increases, then ease as titration settles.
-
Peptide Compounding Pharmacy: What It Does
A peptide compounding pharmacy prepares a prescription for a named patient when no suitable manufactured product meets that patient's need. The meaningful checks are the prescription, the facility's regulatory pathway and its controls for identity, potency and sterility.
-
Thymosin Beta-4: What It Is and How TB-500 Relates
Thymosin beta-4 is a 43-amino-acid protein that helps cells manage actin. TB-500 is a seven-amino-acid synthetic fragment, so research on the parent molecule cannot simply be assigned to the product.
-
CJC-1295 No DAC: What the Label Actually Means
CJC-1295 no DAC is label shorthand for modified GRF 1-29, a short-acting GHRH analog without the albumin-binding feature that makes the DAC form last for days.
-
Does Semaglutide Make You Tired? What Trials Show
Yes, fatigue can happen, though it was reported by a minority of people in STEP trials. The timing and accompanying symptoms help distinguish low intake or dehydration from hypoglycemia or another cause.
-
Semaglutide and Alcohol: What to Know
There is no listed direct interaction between semaglutide and alcohol, but the combination can make nausea, dehydration, low blood sugar, and pancreatitis risk more important.
-
What Happens When You Stop Taking Semaglutide
Appetite commonly returns as semaglutide clears, and some weight regain is likely. Trials show why stopping is better treated as a long-term care decision than as a test of willpower.
-
Does Tirzepatide Make You Tired? What Trials Say
Fatigue was reported by 5–7% of trial participants on tirzepatide against 3% on placebo. The more useful question is what is actually causing it.
-
What Is Kisspeptin-10? The Decapeptide Explained
Kisspeptin-10 is the last ten amino acids of the full 54-residue peptide — the shortest fragment that still switches on the receptor. It also clears from human blood in about four minutes, which shapes everything about how it is given.
-
NAD Injection Side Effects: What Is Reported
Published intravenous data describe transient infusion-associated symptoms in one small retrospective series and no reported adverse events in an earlier slow-infusion pilot; because the studies differed in design and did not randomize infusion rate, they do not establish speed as the cause.
-
SS-31 Peptide Dosage: What the Trials Used
Human elamipretide studies have used multiple regimens, including weight-based intravenous infusions and, in PROGRESS-HF, 4 mg or 40 mg subcutaneously once daily; several later disease trials used 40 mg daily. Those figures are trial parameters rather than a protocol anyone can lift — outside a trial there is no established dose.
-
TB-500 Side Effects: What Is Known and What Is Not
Most of what circulates as a TB-500 side effect list is neither reported nor ruled out. The honest version starts with how thin the human safety data is — and with why a seller's clean record is not one.
-
Does Insurance Cover Tirzepatide? 2026 Guide
Insurance may cover Mounjaro for type 2 diabetes, while Zepbound coverage for obesity or sleep apnea depends on the plan. Compounded tirzepatide is generally self-pay.
-
How Long Does Tirzepatide Stay in Your System?
Tirzepatide usually takes about 25–30 days to fall to a small fraction of its starting level after the last dose. Its five-to-six-day half-life explains that estimate, but side effects and clinical effects do not end on one exact day.
-
Ipamorelin Side Effects: What Human Data Shows
Human safety data for ipamorelin are unusually thin. Short-term reports exist, but no published trial tells us how common side effects are with months or years of compounded use.
Page 13 of 18 · 344 articles